The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

Bhawna Sirohi, R Powles, J Treleaven, +7

Bone Marrow Transplantation

Hematological MalignancyTransplantationMarrow TransplantationImmunologyHematology +8

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?

Seema Singhal, R Powles, J Treleaven, +10

Bone Marrow Transplantation

Hematological MalignancyTransplantationCd34+ Cells/kgStem Cell TransplantationImmunology +4

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

Seema Singhal, R Powles, Bhawna Sirohi, +3

Bone Marrow Transplantation

Hematological MalignancySurvival BenefitMedicineImmunologyMetronomic Chemotherapy +4

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

R Powles, Noopur Raje, S Milan, +8

Bone Marrow Transplantation

Unselected Myeloma PatientsPrognostic EvaluationHematological MalignancyOncologyHematology +4

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

Jayesh Mehta, R Powles, S Kulkarni, +2

Bone Marrow Transplantation

TransplantationImmunologyHematologySingle-center ExperienceLeukemia Relapsing +9

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

Seema Singhal, R Powles, S Kulkarni, +10

Bone Marrow Transplantation

TransplantationMarrow TransplantationBlood Cell YieldsStem Cell TransplantationHematology +6

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Radovan Sašo, S Kulkarni, Philip B. Mitchell, +7

British Journal of Cancer

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

S Kulkarni, R Powles, Bhawna Sirohi, +12

Bone Marrow Transplantation

TransplantationMarrow TransplantationStem Cell TransplantationImmunologyHematology +6

Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

Jayesh Mehta, R Powles, Bhawna Sirohi, +5

Bone Marrow Transplantation

Hematological MalignancyTransplantationMarrow TransplantationMedicineHematology +6

Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)

S Kulkarni, Moses Rodriguez, Alejandro Almería Lafuente, +7

Bone Marrow Transplantation

HepatologyHepatic Veno-occlusive DiseaseLiver PhysiologyPathologyLiver Disease +2